Loading...
•
Mar 31, 2022
NextCure Q1 2022 Earnings Report
Reported first quarter 2022 financial results and provided a business update.
Key Takeaways
NextCure reported its first quarter 2022 financial results, highlighting the advancement of its pipeline of four product candidates and anticipating clinical trial updates for NC318, NC410, and NC762, as well as an IND filing for NC525 in the second half of 2022. The company's cash position is expected to fund operations into the first quarter of 2024.
Advanced pipeline of four product candidates towards key clinical milestones.
Anticipate clinical trial updates for NC318, NC410, and NC762 in the second half of 2022.
Expect an IND filing for NC525 in the second half of 2022.
Cash position of $201.3 million will fund operations into the first quarter of 2024.
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...